XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jul. 01, 2024
Oct. 05, 2023
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Jun. 27, 2024
Dec. 01, 2020
Revenue from Contract with Customer, Excluding Assessed Tax     $ 385,896   $ 837,159 $ 720,513 $ 1,815,211      
Alphazyme [Member]                    
Proceeds from Sale, Maturity and Collection of Investments       $ 61,977       $ 1,300,000    
Alphazyme [Member]                    
Ownership Percentage                   1.99%
Research and Development [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax     385,896   793,042 720,513 1,726,976      
Proliant Agreement [Member]                    
Initial Up Front Payment                 $ 500,000  
Second Payment Upon Completion Transfer                 500,000  
Final Payment Upon Meeting Certain Productivity Threshold                 $ 500,000  
Revenue from Contract with Customer, Excluding Assessed Tax     0     0        
Proliant Agreement [Member] | Subsequent Event [Member]                    
Non-refundable Upfront Payment, Received $ 500,000                  
Inzymes Agreement APS [Member]                    
Non-refundable Upfront Payment, Received   $ 600,000                
Revenue from Contract with Customer, Excluding Assessed Tax     52,000     92,000        
A Global Food Ingredient Company [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax     0     0        
A Global Food Ingredient Company [Member] | Research and Development [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax         226,000   565,000      
A Global Food Ingredient Company [Member] | Success Fees [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax         65,500   65,500      
Janssen Pharmaceutical Companies [Member]                    
Revenue from Contract with Customer, Excluding Assessed Tax     $ 0   191,000 $ 0 380,000      
Deferred License Revenue         $ 44,000   $ 88,000